HIV Acquisition and Life Course of Born-abroad Men Who Have Sex With Men Living in Ile-de-France: the GANYMEDE Study
GANYMEDE
1 other identifier
observational
1,048
1 country
1
Brief Summary
In France, men who have sex with men (MSM) born abroad are the most affected population by HIV, in terms of HIV incidence and prevalence of undiagnosed infections. Close to 50% of born-abroad HIV-infected MSM are living in the region of Ile-de-France, which is the metropolitan area of Paris. Recent European data, not including France, suggest that born-abroad MSM have the highest rate of post-migration HIV acquisition. Many vulnerability factors could explain le burden of HIV in this group of the population. A better understanding of vulnerability factors related to post-migration HIV acquisition should allow to improve HIV prevention and screening strategies among born-abroad MSM living in France. This, in turn, should reduce the burden of HIV in this population in France.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 3, 2020
CompletedFirst Posted
Study publicly available on registry
December 28, 2020
CompletedStudy Start
First participant enrolled
April 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2022
CompletedJuly 22, 2022
July 1, 2022
1.2 years
December 3, 2020
July 21, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Post-migration proportion of HIV acquisition in born-abroad HIV-positive MSM living in Ile-de-France
Estimation of the post-migration proportion of HIV acquisition in born-abroad HIV-positive MSM living in Ile-de-France (proportion of participants, n (%))
Through study completion, an average of 12 months
Secondary Outcomes (1)
Timing of HIV infection for people infected in France
Through study completion, an average of 12 months
Other Outcomes (6)
Phylogenetic analysis in participants having acquired HIV before and after the migration, between them and with other populations
Through study completion, an average of 12 months
Motivations and migratory processes
Through study completion, an average of 12 months
Vulnerability factors
Through study completion, an average of 12 months
- +3 more other outcomes
Interventions
The questionnaire will be translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service, if necessary.
Eligibility Criteria
* Cis-gender men who report having sex with men; * Over 18 years of age; * Type 1 HIV infected; * Born in a country other than France and arrived in France at the age of 15 at the earliest;
You may qualify if:
- Cis-gender men who report having sex with men;
- Over 18 years of age;
- Type 1 HIV infected;
- Born in a country other than France and arrived in France at the age of 15 at the earliest;
- Followed in Ile-de-France for their HIV infection and having consulted at least once in the participating center during the last 12 months;
- Non-opposition to the collection of their health data, after being well informed of the study and the patient rights in accordance with RGPD and LIL (French regulation)
You may not qualify if:
- Somatic or psychiatric pathology making it impossible to participate in an investigation;
- Communication disorder making it impossible to read (or oral responses in the event of assisted questionnaire completion).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Pitié-Salpêtrière, AP-HP, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLESP), INSERM 1136
Paris, 75013, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 3, 2020
First Posted
December 28, 2020
Study Start
April 14, 2021
Primary Completion
June 30, 2022
Study Completion
June 30, 2022
Last Updated
July 22, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share